NCT02013115

Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Academic / Other
• Sex: All
• Age: 12 Hours
• Healthy volunteers: Not accepted

Summary

Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

Conditions

• Respiratory Distress Syndrome

Interventions

Type	Name	Description
DRUG	Budesonide	Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation

Timeline

• Start date: 2015-01-01
• Primary completion: 2017-10-30
• Completion: 2017-10-30
• First posted: 2013-12-17
• Last updated: 2017-12-07

Locations

1 site across 1 country: China